MiR-196a targets inhibitor of growth 5 (ING5) and cyclin-dependent kinase inhibitor 1B (CDKN1B), conferring cisplatin resistance to HNSCC cells [42]. Here, ING5 is linked to head and neck squamous cell carcinoma.